News

Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement

REDWOOD CITY, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing…

9 months ago

Inspire Medical Systems, Inc. Announces Appointment of Carlton Weatherby as Chief Strategy Officer

MINNEAPOLIS, July 24, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on…

9 months ago

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing…

9 months ago

QIAGEN N.V. to release results for Q2 2023 and hold webcast

Venlo, The Netherlands, July 24, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans…

9 months ago

The Garry Hurvitz Centre for Community Mental Health at SickKids Selects VitalHub to implement its TREAT Client Information System to Enhance Client Care

TORONTO, July 24, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) is excited to announce a…

9 months ago

SomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in Europe

SomaLogic’s 7,000-plex SomaScan® Platform will be used in proteomics testing at scale in EuropeBOULDER, Colo. and L’AQUILA, Italy, July 24,…

9 months ago

Quipt Home Medical to Participate at the 43rd Annual Canaccord Growth Conference

Fireside Chat to be Held Wednesday, August 9thCINCINNATI, July 24, 2023 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”)…

9 months ago

Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX),…

9 months ago

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

BOSTON, July 24, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and…

9 months ago